 | | Vol. 15.01 – 16 January, 2024 |
| |
|
|
| Investigators treated 25 patients, 20 pancreatic and five colorectal, who were positive for minimal residual mKRAS disease after locoregional treatment in a Phase I study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909.
[Nature Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors showed that transient stimulation of exocrine cells, derived from juvenile and adult type 1 diabetes donors to the FDA-approved EZH2 inhibitors GSK126 and Tazemetostat influenced a phenotypic shift towards a β-like cell identity.
[Signal Transduction And Targeted Therapy] |
|
|
|
| HOMA2 was used to estimate insulin sensitivity and fasting β-cell function at baseline and one, three, and five years on treatment.
[Diabetes Care] |
|
|
|
| Stem cell derived beta cell clusters (SC-β) cells were resized into small clusters, encapsulated in alginate spheres, and coated with a biocompatible A10 polycation coating that resists fibrosis.
[Small] |
|
|
|
| The majority of adult pig islet grafts transplanted in non-immunosuppressed nonhuman primates resulted in xenograft survival >100 days.
[Science Advances] |
| |
|
|
| Using an immune lipoplex nanoparticle biochip assay, scientists showed that glypican 1 (GPC1) mRNA expression in the exosomes-rich extracellular vesicle (EV) subpopulation and GPC1 membrane protein expression in the microvesicles-rich EV subpopulation, served as a viable biomarker for PDAC.
[Advanced Science] |
|
|
|
| Investigators found that RING finger 43 (RNF43)-mutated pancreatic cancer cells exhibited elevated B-RAF/MEK activity and were highly sensitive to MEK inhibitors.
[Advanced Science] |
|
|
|
| Researchers identified an upregulation of lncRNA FOXD1-AS1 in cancer stem cells (CSCs). The enforced expression of lncRNA FOXD1-AS1 promotes tumorigenesis and self-renewal in pancreatic cancer CSCs.
[Cancer Cell International] |
|  |
|
|
|
| The authors summarize the latest developments in bioengineering functional islet organoids in vitro and promoting vascularization of organoid grafts before and after transplantation.
[Metabolism Clinical And Experimental] |
|
|
|
|
| Lilly Stands Against the Use of its Medicines for Cosmetic Weight Loss: Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss.
[Eli Lilly] |
|
|
|
|
|
February 26 – 27, 2024
Manipal, India |
| |
|
|
|
| | Novo Nordisk – Beijing, China |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | Weill Cornell Medicine – New York City, New York, United States |
|
|
|
| | Michigan State University – East Lansing, Michigan, United States |
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
